Menu

WHO Cherry-Picked Data on Pesticide, Investigation Finds

A group evaluating glyphosate’s cancer risk omitted evidence that the chemical is not carcinogenic.

Oct 22, 2017
Ashley P. Taylor

PIXABAY, SBJ04769Update (October 26): In a statement published October 24, the IARC “rejects these false claims” that it cherry-picked data on glyphosate. IARC explains that the differences between the draft document and the report center around a review paper coauthored by a Monsanto scientist: “. . . the Working Group considered that the review article did not provide adequate information for independent evaluation of the conclusions reached by the Monsanto scientist and other authors; consequently, the draft was revised, and the text in the published Monograph is the consensus opinion of the Working Group.”

IARC stands behind its conclusions.

In writing a report about the cancer risk of glyphosate, a key ingredient in Monsanto’s weed killer Roundup, the World Health Organization (WHO) edited out references to evidence that the pesticide does not cause cancer in animals, Reuters reports in a story published yesterday (October 19).

The original WHO report, issued in 2015 by the International Agency for Research on Cancer (IARC), a semiautonomous group within the WHO, concluded that glyphosate was a “Group 2a carcinogen, a substance that probably causes cancer in people,” according to Reuters. An investigation by Reuters finds that IARC redacted evidence to the contrary from their report.

“IARC members manipulated and distorted scientific data” in the glyphosate report, Scott Partridge, Monsanto’s vice president of global strategy, tells Reuters.

See “E.U. Delays Vote On Roundup

The original report, as published, contradicts other analyses from groups around the world, according to Reuters. A subsequent analysis by a United Nations and WHO panel concluded that glyphosate from food was “unlikely” to pose a cancer risk to humans, for instance. The US Environmental Protection Agency and the European Food Safety Authority and the European Chemicals Agency have called glyphosate safe.

The conclusions of that 2015 report have had political consequences. Since its publication, Monsanto has faced litigation in the U.S. from people claiming that the pesticide caused their cancer. In the European Union (E.U.), a pending vote will determine whether to renew glyphosate’s license for sale in EU member states. If the vote is negative, glyphosate will be banned in the E.U. as of January 1, according to Reuters.

Reuters’s investigation suggests that those conclusions might have been different had the report been edited differently. “Reuters found 10 significant changes that were made between the draft chapter on animal studies and the published version of IARC’s glyphosate assessment,” according to the news report. “In each case, a negative conclusion about glyphosate leading to tumors was either deleted or replaced with a neutral or positive one. Reuters was unable to determine who made the changes.”

In two cases, for example, the report included a new statistical analysis that flipped the conclusion of a study from there being no significant link between glyphosate and cancer in mice to an association that was statistically significant, according to Reuters.

The IARC did not answer Reuters’s questions about changes to the report.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.